Who to Treat
For prostate cancer has been a huge challenge. These tests help us determine who is at low risk for their disease to ever cause a problem and who will benefit from treatment.
ProMark is an advanced prognostic test developed specifically for prostate cancer. If you have a biopsy Gleason score 3+3 or 3+4, ProMark uses automated image recognition technology to predict risk of having an aggressive prostate cancer.
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next step.
Prolaris is a measure of how fast a prostate cancer tumor is growing. Biopsy tissue samples can be used to determine a patient’s personal Prolaris Score. Studies have shown that Prolaris provides an accurate assessment of cancer aggressiveness.
The Oncotype DX Gemonic Prostate Score harnesses the power of genomics to provide a more precise and accurate assessment of risk based on individual tumor biology.